Member Info for CHELSEA7

Hi chester/violindog, count me in as one of |"us|" too.

Violindog, good to hear from you.

Vulpes also increased their holdings in OBD last Monday, and there was not any additional information in Box 11

JohnyB1, thanks for posting that. On Monday I posted under RNS just a..... ? which was exactly a reference to that which checking later nobody picked up on.

I look forward to any comments, as you do, with regard to that.

Burble, many thanks to you for all your efforts on our behalf with regard to potential media news and for your great research too.

Have a great weekend guys, and excited about FPD, the last couple of months has been dreadful to watch, just the pick up I, and I am sure many needed. ATB

19/4 Tuesday for me

And me Matt, it was indeed a no nonsense we are ready RNS, with another due very soon.

Afternoon LL, well we were waiting on criteria changes to ensure a quicker trial and easier recruitment.

Does anyone think we could be doing the same thing with SCB1/2 given the poor recruitment response.?

Berm/ciasKin correct re GSK, a very speculative rise and my point really was we don"t get the same bnefit of the doubts as SAR and VAL do. My cofidence in general has been at a low ebb recently, bu again the tone and wording of our RNS has allayed those fears largely. I wasn" trying to knock SAR and VAL at all it is just interesting to what it takes to act as a driver between certain shares on Patent news just for example.

I am confident by virtue of that to get the FPD very shortly

Night, a good week

For 50k, time for a tick up before the break!!!

Welcome back AB, just your second post all week, but I guess you feel it is time to start your constant negativity again, and twisting the points.

Mind you your friends haven"t been seen all week, what a pleasure t has been.

Agree roses, after a couple of false starts I feel we are ready to push on now, and the tone of the RNS to me said it all.

Have a great Easter all.

Hi rigga, I get your point. The reason for SARs big 2 day rise was Patent approved RNS on Monday, so there has been no further news since then.

They must have risen over 50% on that alone. How come with all the Patents we have approved we never rise like that? Another oddity of AIM

I asked on Tuesday whether anybody understood why SAR were valued at £233m and Sclp £131m. Genuine queston I know little about SAR but was surprised to see the valuations.

Well 48 hours later SAR is now £167m and SCLP is £141m. What has changed news wise? Nothing!!!!

Morning c11, it would be good but as a few of us have said I think we will get interviews and news artIcle when we release the FD RNS.

As per my conversation with Bermuda yesterday re waiting for efficac data in 2023 I do believe on the basis of hw quickly tumours have melted in mice we will get interim efficacy announcements well before that. Can we only imagine the market reaction if we announce result in humans anywhere near those in clinic?

It is for that reason I am going to hang on to all my shares for now

Bermuda, thanks, that is what I am hoping for ATB

Bermuda, what I dont understand is by removing one of the cohorts to speed up the trial is why we have to wait until 2023 for efficacy data? Any thoughts

Chester/Crumbs,

Agree with both of you good points. It makes sense to do interviews on FPD, and that could well give rise to the momentum to take us to the 30p mark which Ruck suggests....28p/38p

Lets not forget we are dealing with desperately ill patients, so no I cannot see delays in getting FPD and I am pretty sure that with the support we are being given first patients will be stepping forward as we speak. Time is of the essence heread regardless of financial benefits it feels really good for me to see us back into the fray, treating cancer, saving lives, the reason many of us were attracted to this particular share all those years ago. Two days running now the MMs have taken us down early doors, but good support at 16.50.

I agree chester, hence why very soon.

Good to see IMM and SAR gaining big.

Interesting SAR M/C IS now £233m..................Scancell just £133m...................does that make sense to anyone/Ruck?

Ruck, it would make sense to me to have it on hold. Modite trial wil take up a hell of a lot of resources ot to metin the COVIDITY trial underway already and hopefully expanding now.

Would you agree a successful COVIDITY trial would be sufficient enough to attract bids for Immunobody. We can then also put any further/ remaining resources into Glycan mabs etc. I think the SCIB trials would stretch us at the expense of what is now in place?

Burble, dare I say imminent. The RNS was a real we mean business one and it would seem early recruitment is alreaddy underway.

I am sure Scancell have been very mindfall of the problems recruiting and have done all in their power not to repeat that. That is a lot of sites already organised. Just MO

There is one 100k buy showing now at 16.64.

We oped down .25p at 16.5/17.5

could be some 200k buys delayed to come, volumes do not tally, think MMs are treeshaking this morNing IMHO

Ruck, I have thought for some time that the SCIB trials are on hold, possibly waiting for criteria changes for recruitment but certainly waiting for COVIDITY data to validate Immunobody further